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Introduction {#sec004}
============

The dental pulp is equipped to express numerous mediators of inflammation, which can combat irritating factors \[[@pone.0167289.ref001]--[@pone.0167289.ref004]\]. Its mechanistic response begins with vascular changes mediated by Toll-like receptors (TLR) 4/2-positive cells and includes release of measurable inflammatory mediators such as IL-8, IL-6, IL-1 and others \[[@pone.0167289.ref004]--[@pone.0167289.ref007]\]. Under normal physiologic conditions (left in [Fig 1](#pone.0167289.g001){ref-type="fig"}), the vasculature consists of central vessels that branch out into a plexus towards the periphery and specifically the pulp horns. An important difference from soft tissue-enclosed portions of the body is that dental hard tissues enclose the pulp creating a low compliance environment. Dental blood vessels are mainly under control by local metabolites and less by sympathetic innervation. The main cellular components of the pulp are peripherally located odontoblasts and stromal fibroblasts. There are also undifferentiated mesenchymal cells found mainly in the paravascular niche and immune cells ([Fig 1](#pone.0167289.g001){ref-type="fig"}). In health, neutrophils predominate but dendritic cells and occasional macrophages are also found.

![Schematic illustration of a tooth with a healthy pulp (left panel) and an inflamed pulp (right panel) subjacent to a caries lesion.\
Involved factors and biological effectors are indicated for both pulpal conditions.](pone.0167289.g001){#pone.0167289.g001}

Inflammation of the dental pulp (pulpitis) has been viewed as a tightly regulated sequence of vascular and cellular events mediated by molecular factors \[[@pone.0167289.ref008]\]. Pulpitis is typically caused by an opportunistic infection of the pulp space by commensal oral microorganisms \[[@pone.0167289.ref009]\]. The most common route of entry for the microorganisms is dental caries. Other potential pathways for pulpal microbial infection include trauma, dentinal cracks, exposed dentinal tubules or the main apical foramen \[[@pone.0167289.ref010]\]. Cells in human dental pulp that express TLR contribute trigger immune responses to microorganisms and their by-products \[[@pone.0167289.ref002]--[@pone.0167289.ref004]\]. This group includes odontoblasts \[[@pone.0167289.ref011]\], endothelial cells \[[@pone.0167289.ref012]\] as well as macrophages and dendritic cells \[[@pone.0167289.ref013]\]. Some of these cells may form mechanical barriers (i.e. odontoblasts), detect and transmit sensations (nerve fibers) or differentiate (i.e. dental pulp stem cells) to limit infection, signal injury and promote repair, respectively.

Based on the patients' signs, symptoms, and examination, four clinical pulpal conditions are described: normal, reversibly inflamed, irreversibly inflamed or necrotic \[[@pone.0167289.ref014]\]. Histology represents the gold standard to determine the inflammatory state of pulp tissue \[[@pone.0167289.ref015], [@pone.0167289.ref016]\]; however, it is generally agreed that histologic and clinical classification of pulpal diagnosis still needs to be improved and refined. Normal and necrotic pulps have straightforward histological presentation. The conundrum lies in differentiating reversible and irreversible pulpitis. Based on histological reports, reversible pulpitis is characterized by the absence of bacteria and by localized coagulation and liquefaction necrosis immediately surrounding the irritant, whereas irreversible pulpitis is characterized by the presence of the bacteria or their by-products in the dental pulp and by preponderance of acute inflammatory cells predominantly neutrophils in the tissue beneath the lesion suggesting chemotactic activity. Lysosomal enzymes discharged by neutrophils result in widespread tissue damage and suppuration \[[@pone.0167289.ref016]--[@pone.0167289.ref018]\]. Acute pulpitis (reversible, and irreversible) can be an extremely painful condition and is believed to be one of the main causes for patients to seek emergency dental treatment during or after office hours \[[@pone.0167289.ref019], [@pone.0167289.ref020]\]. The main clinical difference between reversible and irreversible pulpitis is in the pulp's response to thermal stimulus. Reversible pulpitis presents an exaggerated yet non-lingering response to cold stimulus. Irreversible pulpitis on the other hand is characterized by constant, spontaneous pain with exaggerated and lingering response to cold stimulus. However, forty percent of teeth with irreversible pulpitis can be painless \[[@pone.0167289.ref021]\]. In reversible pulpitis, the pulp is expected to recover after removal of the causative stimulus. In contrast, if the pulp is irreversibly inflamed, healing is not expected and pulpectomy (i.e., full removal of the dental pulp) is indicated.

The succession of signaling events resulting from dental pulp stimulation by microorganisms to the release of an array of immune mediators that in turn may cause pulpal or odontogenic pain, pulpitis, or in advanced stages, pulpal necrosis and finally apical periodontitis have been well described in the past \[[@pone.0167289.ref004]--[@pone.0167289.ref007]\]. Detailed discussion of these mechanisms is beyond the scope of this article.

Currently, diagnostic procedures that aim to assess pulpal inflammation involve case history, as well as clinical and radiographic examination. Clinical examination includes different procedures such as inspection, pulp sensitivity to thermal or electric stimuli, and pain on palpation or percussion. These procedures apparently did not change much in the last century \[[@pone.0167289.ref022]\]. However, the validity of the currently employed clinical tests to determine the actual or histopathological status of the pulp remains controversial \[[@pone.0167289.ref015]\]. A recently performed literature review summarized the available information on the diagnostic accuracy of signs/symptoms and current tests used to determine the condition of the pulp \[[@pone.0167289.ref023]\]. These authors concluded that the overall evidence was insufficient to support the accuracy of such test, even if the tests are combined. Hence, the current diagnostic procedures do not reliably identify the inflammatory status of the pulp. This is particularly unfortunate since decision making in this field, for example differentiation between vital pulp therapy and root canal treatment, critically depends on an accurate pulpal diagnosis.

According to the National Library of Medicines, the medical subject heading term (MeSH term) definition for a biological marker is a measurable and quantifiable biological parameter that serves as an indicator for health- and physiology-related assessments. Molecules expressed in the cascade of tissue inflammation may serve as (diagnostic) biomarkers for the presence of inflammation. Some research suggests that the dental pulp is not an isolated entity in an encased, solid environment but a reactive tissue that extends its biological products into the outside environment \[[@pone.0167289.ref024], [@pone.0167289.ref025]\]. In fact, studies have shown that pulpal events can be reflected through measurable levels of protein markers that correlated with pulpal symptoms in pulpal blood \[[@pone.0167289.ref026]\], dentinal fluid \[[@pone.0167289.ref027]\], periapical fluid \[[@pone.0167289.ref028]\], and gingival crevicular fluid (GCF; \[[@pone.0167289.ref001], [@pone.0167289.ref029]\]).

In the field of periodontology, biomarkers in oral fluids/saliva or gingival crevicular fluid are used to detect the occurrence and progression of periodontitis \[[@pone.0167289.ref030], [@pone.0167289.ref031]\]. For example, matrix metalloproteinases (MMPs) such as MMP-8 and -9 have been shown to be central biomarkers of soft tissue breakdown in periodontal pockets \[[@pone.0167289.ref032]\]. Periodontal and pulpal inflammation shares certain features: initially, both exhibit soft-tissue inflammation caused by microbial infection. At a later stage, these pathologic processes culminate in bone resorption (vertical bone-loss or apical periodontitis, respectively). It is therefore possible that both pathoses may express the same biomarkers. In this regard, MMPs were shown to be potential biomarker for both pulpal \[[@pone.0167289.ref033]\] and periodontal disease \[[@pone.0167289.ref032]\]. However, the application of molecular diagnostics in pulpal disease is as yet not used for clinical decision-making \[[@pone.0167289.ref034]\].

Previous studies have investigated the molecular regulatory pathways of pulpal inflammation employing explanted cell cultures *in vitro* \[[@pone.0167289.ref035]--[@pone.0167289.ref037]\]. However, the extrapolation of such results to the clinical situation is difficult, perhaps due to the reductionist nature of such experiments. *In vivo*, the presence of other cellular players (e.g. immune cells), inhibitory proteins (e.g. protease inhibitors) and other molecules that modify the inflammatory response may present a completely different inflammatory response and consequently, a different clinical outcome compared with what may be suggested by *in vitro* experimental results. Studies reporting clinical samples for the presence of potential biomarkers for pulpal inflammation are still on the rise. The clinical importance of identifying these biomarkers that can be used to diagnose or to stage pulpal inflammation warrants not only additional studies but also a critical or systematic review and analysis of published reports. Therefore, the aim of this paper is to systematically review the currently available information on biomarkers that were identified from pulp tissues diagnosed as normal or inflamed.

Systematic Review {#sec005}
=================

Eligibility Criteria and Literature Search {#sec006}
------------------------------------------

This systematic review was prepared in accordance with PRISMA ([S1 Table](#pone.0167289.s001){ref-type="supplementary-material"}) \[[@pone.0167289.ref038]\]. Studies were eligible for inclusion to the review that clinically and/ or histologically differentiate between a healthy and a irreversibly inflamed pulp in permanent human teeth, and analyzed interstitial/ dentinal liquor, gingival crevicular fluid, pulpal tissue, dentin fluid or apical blood for the presence of a biological marker. A biological marker is defined as measurable and quantifiable biological molecule that theoretically can be present in those substrates and might serve as an indicator for a healthy or diseased pulp (adapted from MeSH Unique ID: D015415). An electronic search strategy with combined keywords and indexing vocabulary (MeSH terms) was conducted in the Medline database of the US National Library of Medicine employing the OvidSP interface. We used the following search terms and other subject headings: 'pulpitis', 'acute pulpitis', 'irreversible pulpitis', 'painful pulpitis', 'biological markers', 'inflammation mediators', 'dentinal fluid', and 'gingival crevicular fluid'. [S2 Table](#pone.0167289.s002){ref-type="supplementary-material"} lists the detailed search strategy performed in Medline. The same electronic search strategy was used in Biosis (OvidSP), the Cochrane library (Wiley), Embase (<http://www.embase.com>) and the Web of Science (Thomson Reuters). The last date entered was February 19, 2015. No language restrictions were imposed and all articles were included from the inception of the respective database ([S3 Table](#pone.0167289.s003){ref-type="supplementary-material"}). To ensure the completeness of the search, one reviewer (DRK) conducted a thorough search of the bibliographies of all included studies.

Study Selection and Quality Assessment {#sec007}
--------------------------------------

The search and selection process is summarized in [Fig 2](#pone.0167289.g002){ref-type="fig"} \[[@pone.0167289.ref038]\]. A pool of 1733 records was initially identified using the electronic search strategy and other sources. After removal of duplicates, 851 records remained. Two reviewers (DKR and JCG) independently screened the titles and abstracts of the references collected. Communications not related to the topic were discarded (n = 695). Communications deemed appropriate by one of the reviewers were assigned for full text evaluation. One hundred and fifty-six records were identified using this approach and reviewed as full texts. Articles were collected and evaluated independently by both reviewers. Non-English abstracts or manuscripts were translated with the help of translators. Further articles (n = 99) were excluded for one of the following reasons: i) studies not on human teeth, ii) cell culture study only, iii) no potential biomarker was investigated or the study was off topic, iv) no clear distinction between reversible, irreversible or necrotic pulp, v) studies rather on histologic features or presence of cells, bacteria or viruses than on quantification of a biomarker, vi) review articles, editorials, comments, abstract only or case reports ([S4 Table](#pone.0167289.s004){ref-type="supplementary-material"}). In case of disagreement consensus was achieved through discussion by third party arbitration (OAP). Articles where no exclusion criteria applied were included to the review. There was 94.2% agreement prior to arbitration between both reviewers and finally 57 publications were included to the review. The included articles were written in English (n = 54) or Chinese (n = 3) language.

![PRISMA flowchart depicting the systematic selection and exclusion of articles related to the topic.\
A detailed description of the excluded articles with the respective reasons for exclusion is presented in the running text and [S4 Table](#pone.0167289.s004){ref-type="supplementary-material"}. *From*: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *P*referred *R*eporting *I*terns for Systematic Reviews and *M*eta-*A*nalyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi: [10.1371/journal.pmed1000097](http://dx.doi.org/10.1371/journal.pmed1000097) **For more information, visit** [www.prisma-statement.org](http://www.prisma-statement.org).](pone.0167289.g002){#pone.0167289.g002}

Quality Assessment {#sec008}
------------------

The quality of the included studies was assessed using a modification of the Newcastle-Ottawa-Scale (NOS; \[[@pone.0167289.ref039], [@pone.0167289.ref040]\]). The NOS rates the 3 study domains 'selection', 'comparability' and 'outcome'. Each positive rating was awarded with a star. The parameters recorded for 'selection' were: selection of the cohort (gender and age distribution reported) and condition of the cohort (general health and medication reported). The parameters recorded for 'comparability' were: diagnostics of cases and controls (anamnesis, clinical and radiological inspection described in sufficient detail), histological confirmation of the diagnosis performed (yes/no), quality of the controls (control sample from the same patient as the case sample) and the ratio of the group size (cases:controls ≥ 1:2). The parameters recorded for 'outcome' were: reported blinding to the case/control status (yes/no) and that the same tests were performed with the cases and control samples (yes/no). Consequently two stars could be awarded for 'selection', four stars for 'comparability' and two stars for 'outcome'. A value of '0' represents the lowest study quality and '8' the highest possible quality rating of the modified NOS.

Data Extraction and Statistical Analysis {#sec009}
----------------------------------------

Quantitative data were collected from all studies included to the review. An electronic protocol for data extraction was defined and piloted on several manuscripts before final completion. Relevant information regarding reference name, publication date, substrate analyzed for the presence of a biological marker, how was the substrate collected, number of specimens in experimental group and control group, was the substrate pooled before analysis (yes/no), name of the biological marker under investigation, what type of molecule is the biological marker, what general function serves the biological marker, what was the molecular expression level of the biological marker, which analyte was evaluated for the presence of the biological marker, which method was used for analysis, and were statistically significant differences between specimens of the irreversible pulpitis group compared to the control group (healthy pulp) reported (yes/no), were collected. The synthesis of the data is presented in a descriptive manner. Moreover, descriptive statistics were applied when deemed appropriate (JMP 10.0.0, SAS Institute, Cary, N.C., USA).

Results {#sec010}
=======

Study Characteristics and Quality Assessment {#sec011}
--------------------------------------------

The studies excluded during full text evaluation (N = 99; [Fig 2](#pone.0167289.g002){ref-type="fig"}) are presented in [S4 Table](#pone.0167289.s004){ref-type="supplementary-material"}. The studies included in the review are listed in Tables [1](#pone.0167289.t001){ref-type="table"} and [2](#pone.0167289.t002){ref-type="table"}. Due to the heterogeneous nature of the studies it was not possible to perform meta-analysis on their outcome. The quality ratings of the included studies according to the modified NOS are presented, along with the full reference, in [S5 Table](#pone.0167289.s005){ref-type="supplementary-material"}. The average quality score was 3.9 ± 1.1 (mean ± SD). [Fig 3](#pone.0167289.g003){ref-type="fig"} provides an overview on the total ratings for the respective parameters for the study domains selection, comparability and outcome. Weaknesses were noticed for the parameters selection of the cohort, quality of the controls and reported blinding to the case/control status.

10.1371/journal.pone.0167289.t001

###### Studies assessing pulp tissue for the presence of biomarkers associated with pulpal condition.

![](pone.0167289.t001){#pone.0167289.t001g}

  Reference                                                                                                                 *n* per group (irreversibly inflamed/ non-inflamed)   Biomarker                      Function                                                                                                                                                    Target             Analyte                                     Method            Significant difference between groups
  ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ------------------------------------------- ----------------- ---------------------------------------
  **Cytokines**                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Zehnder et al. 2003 \[[@pone.0167289.ref048]\]                                                                            11/13                                                 IL-1α                          Regulates immune and inflammatory reactions; stimulates bone resorption                                                                                     mRNA               PTS                                         RT-PCR            n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 IL-1rα                         Acute phase protein that increases neutrophil presence of                                                                                                   Protein            PTS                                         Multiplex assay   y
  Zehnder et al. 2003 \[[@pone.0167289.ref048]\]                                                                            11/13                                                 IL-1β                          Regulates immune and inflammatory reactions; stimulates bone resorption                                                                                     mRNA               PTS                                         RT-PCR            n
  Paris et al. 2009 \[[@pone.0167289.ref050]\]                                                                              10/7                                                                                                                                                                                                                                             mRNA               PTS                                         RT-PCR            y
  Silva et al. 2009[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref051]\]                                         5/5                                                                                                                                                                                                                                              Protein            PTS                                         ELISA             n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   y
  Rauschenberger et al. 1997[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref052]\]                                15/17                                                 IL-2                           Regulates activities of leukocytes                                                                                                                          Protein            PTS                                         ELISA             y
  Anderson et al. 2002 \[[@pone.0167289.ref053]\]                                                                           32/24                                                                                                                                                                                                                                            Protein            PTS                                         ELISA             n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 IL-4                           Key regulator in humoral and adaptive immunity; stimulates activated B cells, T-cell proliferation, and the differentiation of B-cells into plasma cells    Protein            PTS                                         Multiplex assay   y
  Zehnder et al. 2003 \[[@pone.0167289.ref048]\]                                                                            11/13                                                 IL-6                           Regulator of T- and B-cell growth, acute phase protein production                                                                                           mRNA               PTS                                         RT-PCR            y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 IL-7                           Stimulates proliferation and maturation of B and T cells                                                                                                    Protein            PTS                                         Multiplex assay   y
  Huang et al. 1999[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref054]\]                                         14/15                                                 IL-8                           Recruitment and activation of neutrophils                                                                                                                   Protein            PTS                                         ELISA             y
  Zehnder et al. 2003 \[[@pone.0167289.ref048]\]                                                                            11/13                                                                                                                                                                                                                                            mRNA               PTS                                         RT-PCR            y
  Silva et al. 2009[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref051]\] [\*](#t001fn001){ref-type="table-fn"}   5/5                                                                                                                                                                                                                                              Protein            PTS                                         ELISA             n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 IL-12p40                       Subunit of IL-12; acts on T- and natural killer cells                                                                                                       Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 IL-13                          Mediator of allergic inflammation and disease                                                                                                               Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 IL-15                          Induces proliferation of natural killer cells                                                                                                               Protein            PTS                                         Multiplex assay   n
  Zehnder et al. 2003 \[[@pone.0167289.ref048]\]                                                                            11/13                                                 IL-18                          Pro-inflammatory cytokine involved in cell mediated immunity                                                                                                mRNA               PTS                                         RT-PCR            y
  Pezelj-Ribaric et al. 2002 \[[@pone.0167289.ref055]\]                                                                     19/18                                                 TNF-α                          Delays neutrophil apoptosis                                                                                                                                 Protein            PTS                                         ELISA             y
  Kokkas et al. 2007 \[[@pone.0167289.ref043]\]                                                                             6/6                                                                                                                                                                                                                                              mRNA               PTS                                         RT-PCR            y
  Keller et al. 2009 \[[@pone.0167289.ref056]\]                                                                             5/5                                                                                                                                                                                                                                              mRNA               PTS                                         RT-PCR            y
  Paris et al. 2009 \[[@pone.0167289.ref050]\]                                                                              10/7                                                                                                                                                                                                                                             mRNA               PTS                                         RT-PCR            y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 TNF-β                          Mediates a large variety of inflammatory, immunostimulatory, and antiviral responses                                                                        Protein            PTS                                         Multiplex assay   n
  Li et al. 2011[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref057]\]                                            4/4                                                   MIP-1α                         Mediate immune responses towards infection and inflammation; activation of granulocytes                                                                     mRNA               PTS                                         RT-PCR            y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 MIP-1β                         Mediate immune responses towards infection and inflammation; activation of granulocytes                                                                     Protein            PTS                                         Multiplex assay   y
  Nakanishi et al. 2005[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref058]\]                                     8/5                                                   MIP-3α                         Chemoattractant for lymphocytes and neutrophils                                                                                                             Protein            FPT                                         IHC               n/a
  Nakanishi et al. 2005[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref058]\]                                     8/5                                                   CCR6                           MIP-3α Receptor on memory T-cells, dendritic cells and Th17 cells                                                                                           Protein            FPT                                         IHC               n/a
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 TGF-α                          Induces epithelial development and wound healing                                                                                                            Protein            PTS                                         Multiplex assay   y
  Piattelli et al. 2004[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref059]\]                                     20/23                                                 TGF-β1                         Modulates pro-inflammatory cytokine production, inhibits mitogenic effects of IL-2 on T and B lymphocytes, blocks activity of other immunocompetent cells   Protein            FPT                                         IHC               y
  Adachi et al. 2007[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref060]\]                                        9/4                                                   CXCL10                         Chemoattractant for monocytes/macrophages, T cells, NK cells, and dendritic cells                                                                           Protein            PTS                                         RT-PCR            y
                                                                                                                            5/4                                                                                                                                                                                                                                              Protein            FPT                                         IHC               n/a
  Jiang et al. 2008[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref061]\]                                         6/5                                                   SDF-1                          Chemotactic for lymphocytes                                                                                                                                 mRNA               PTS                                         RT-PCR            y
                                                                                                                            4/4                                                                                                                                                                                                                                              Protein            FPT                                         IHC               n/a
  Huang et al. 2009[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref062]\]                                         15/15                                                 Oncostatin M                   Involved in hematopoiesis, tissue remodelling processes and inflammation                                                                                    mRNA               PTS                                         RT-PCR            y
                                                                                                                                                                                                                                                                                                                                                                             Protein            FPT                                         IHC               y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 GM-CSF                         Stimulates production of granulocytes and monocytes                                                                                                         Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        GRO                            Neutrophil chemoattractant. Involved in angiogenesis, inflammation, wound healing and tumorigenesis                                                         Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        MCP-1                          Chemoattractant for monocytes, recruits memory T cells, and dendritic cells to the sites of inflammation                                                    Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        MCP-3                          Chemoattractant for monocytes; regulates macrophage function                                                                                                Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        MDC                            Chemotactic for monocytes, dendritic cells and natural killer cells                                                                                         Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        INF-α                          Antiviral agents, modulate functions of the immune system                                                                                                   Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        G-CSF                          Stimulates proliferation and differentiation of granulocytes                                                                                                Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        Eotaxin-1                      Recruits eosinophils by inducing their chemotaxis                                                                                                           Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        flt3ligand                     Stimulates proliferation and differentiation of various blood cell progenitors                                                                              Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        Fractalkine                    Chemoattractant for T cells and monocytes; promotes strong adhesion of leukocytes to activated endothelial cells                                            Protein            PTS                                         Multiplex assay   y
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        CD40L                          Co-stimulatory molecule for T cells; promotes B cell maturation and function                                                                                Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        sIL-2rα                        Receptor that mediates IL-2 activities; increased levels biological fluids correlate with increased immune system activation                                Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        IP-10                          Chemoattractant for monocytes/macrophages, T cells, NK cells, and dendritic cells                                                                           Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        PDGF-AA                        Receptor that regulates cell proliferation, cellular differentiation, cell growth and development                                                           Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        PDGF-AB/BB                     Receptor that regulates cell proliferation, cellular differentiation, cell growth and development                                                           Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        RANTES                         Chemoattractant for leukocytes to inflammatory sites; proliferation and activation of natural-killer cells                                                  Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                                                                        Osteocalcin                    Regulation of bone mineralization                                                                                                                           Protein            PTS                                         Multiplex assay   y
                                                                                                                                                                                                                                                                                                                                                                             Protein            FPT                                         IHC               n/a
  **Proteases and other enzymes**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Gusman et al. 2002 \[[@pone.0167289.ref063]\]                                                                             17/18                                                 MMP-1                          Regulator of connective tissue remodeling                                                                                                                   Protein            PTS                                         ELISA             *Not detected*
  Gusman et al. 2002 \[[@pone.0167289.ref063]\]                                                                             17/18                                                 MMP-2                          Hydrolysis of intercellular matrix                                                                                                                          Protein            PTS                                         ELISA             y
  Accorsi-Mendonca et al. 2013 \[[@pone.0167289.ref064]\]                                                                   10/10                                                                                                                                                                                                                                            Protein            PTS                                         Zymography        y
  Accorsi-Mendonca et al. 2013 \[[@pone.0167289.ref064]\]                                                                   10/10                                                 pro-MMP-2                      Pro-form of MMP-2                                                                                                                                           Protein            PTS                                         Zymography        n
  Gusman et al. 2002 \[[@pone.0167289.ref063]\]                                                                             17/18                                                 MMP-3                          Hydrolysis of intercellular matrix                                                                                                                          Protein            PTS                                         ELISA             y
  Tsai et al. 2005[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref065]\]                                          14/14                                                                                                                                                                                                                                            mRNA               PTS                                         RT-PCR            y
                                                                                                                                                                                                                                                                                                                                                                             Protein            FPT                                         IHC               y
  Gusman et al. 2002 \[[@pone.0167289.ref063]\]                                                                             17/18                                                 MMP-9                          Hydrolysis of intercellular matrix; regulatory factor for neutrophil migration across basement membrane                                                     Protein            PTS                                         ELISA             y
  Suwanchai et al. 2012 \[[@pone.0167289.ref066]\]                                                                          7/18                                                                                                                                                                                                                                             Protein            PTS                                         Western Blot      y
  Accorsi-Mendonca et al. 2013 \[[@pone.0167289.ref064]\]                                                                   10/10                                                                                                                                                                                                                                            Protein            PTS                                         Zymography        n/a
  Huang et al. 2005[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref067]\]                                         17/13                                                 t-PA                           Involved in soft-tissue breakdown; catalyzes the conversion of plasminogen to plasmin                                                                       mRNA               PTS                                         RT-PCR            y
                                                                                                                                                                                                                                                                                                                                                                             Protein            FPT                                         IHC               n/a
  Huang et al. 2007[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref068]\]                                         22/9                                                                                                                                                                                                                                             Protein            PTS                                         Zymography        y
                                                                                                                            22/9                                                                                                                                                                                                                                             Protein            PTS                                         ELISA             y
  Ge et al. 1996 \[[@pone.0167289.ref069]\]                                                                                 12/9                                                  SOD                            Antioxidant                                                                                                                                                 Protein activity   PTS                                         Enzyme assay      y
  Tulunoglu et al. 1998 \[[@pone.0167289.ref070]\]                                                                          10/7                                                                                                                                                                                                                                             Protein activity   PTS                                         Enzyme assay      n
  Bodor et al. 2007 \[[@pone.0167289.ref071]\]                                                                              16/10                                                 Cu, ZN-SOD                     Protection against reactive oxygen species                                                                                                                  mRNA               PTS                                         RT-PCR            y
  Varvara et al. 2005 \[[@pone.0167289.ref072]\]                                                                            13/12                                                                                                                                                                                                                                            Protein activity   PTS                                         Enzyme assay      y
  Bodor et al. 2007 \[[@pone.0167289.ref071]\]                                                                              16/10                                                 Mn-SOD                         Protection against reactive oxygen species                                                                                                                  mRNA               PTS                                         RT-PCR            y
  Ge et al. 1996 \[[@pone.0167289.ref069]\]                                                                                 12/9                                                  MDA                            Oxidative stressor                                                                                                                                          Protein activity   PTS                                         Enzyme assay      y
  Cootauco et al. 1993[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref073]\]                                      5/8                                                   Elastase                       Cleavage of elastin, collagen, proteoglycans                                                                                                                Protein            FPT                                         IHC               y
                                                                                                                                                                                  Cathepsin-G                    Proteolysis                                                                                                                                                 Protein            FPT                                         IHC               y
  Spoto, Fioroni, Rubini, Tripodi, Di Stilio, et al. 2001 \[[@pone.0167289.ref074]\]                                        10/10                                                 Alkaline phosphatase           Hydrolysis of phosphate ester-bonds                                                                                                                         Protein activity   PTS                                         Enzyme assay      n
  Spoto, Fioroni, Rubini, Tripodi, Perinetti, et al. 2001 \[[@pone.0167289.ref075]\]                                        20/20                                                 Aspartate Aminotransferase     Catalyzes transfer of aminotransferase amino group of aspartate to α-ketoglutarat                                                                           Protein activity   PTS                                         Enzyme assay      n
  Esposito, Varvara, Caputi, et al. 2003 \[[@pone.0167289.ref076]\]                                                         15/18                                                 Catalase                       Catalyzes the breakdown of hydrogen peroxide                                                                                                                Protein activity   PTS                                         Enzyme assay      y
  Esposito, Varvara, Murmura, et al. 2003 \[[@pone.0167289.ref077]\]                                                        12/11                                                                                                                                                                                                                                            Protein activity   PTS                                         Enzyme assay      y
  da Silva et al. 2008[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref078]\]                                      6/6                                                   NADPH-diaphorase               Detoxification to produce ROS                                                                                                                               Protein            FPT                                         IHC               y
  Di Nardo Di Maio et al. 2004[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref079]\]                              10/10                                                 eNOS                           Nitric oxide synthase                                                                                                                                       mRNA               PTS                                         RT-PCR            y
                                                                                                                                                                                                                                                                                                                                                                             Protein            PTS                                         Western blot      y
                                                                                                                                                                                                                                                                                                                                                                             Protein            FPT                                         IHC               y
                                                                                                                            10/10                                                 iNOS                           Nitric oxide synthase                                                                                                                                       mRNA               PTS                                         RT-PCR            y
                                                                                                                                                                                                                                                                                                                                                                             Protein            PTS                                         Western blot      y
                                                                                                                                                                                                                                                                                                                                                                             Protein            FPT                                         IHC               y
  Spoto, Ferrante, et al. 2004 \[[@pone.0167289.ref080]\]                                                                   6/12                                                  cGMP PDE                       Hydrolysis of cyclic nucleotide                                                                                                                             Protein activity   PTS                                         Enzyme assay      y
  Spoto, Menna, et al. 2004 \[[@pone.0167289.ref081]\]                                                                      6/12                                                  cAMP PDE                       Hydrolysis of cyclic nucleotide                                                                                                                             Protein activity   PTS                                         Enzyme assay      y
  Accorsi-Mendonca et al. 2013 \[[@pone.0167289.ref064]\]                                                                   10/10                                                 TIMP-2                         Inhibits MMP-2                                                                                                                                              Protein            PTS                                         ELISA             y
                                                                                                                                                                                  MPO                            Generation of reactive oxygen species                                                                                                                       Protein activity   PTS                                         Enzyme assay      y
  **Inflammatory mediators**                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Bolanos and Seltzer 1981 \[[@pone.0167289.ref082]\]                                                                       17/7                                                  cAMP                           Activation of protein kinases                                                                                                                               Protein            PTS                                         RIA               n
                                                                                                                                                                                  cGMP                           Activation of protein kinases                                                                                                                               Protein            PTS                                         RIA               n
  Cohen et al. 1985 \[[@pone.0167289.ref047]\]                                                                              13/20                                                 PGE2                           Multiple pro-inflammatory and immunomodulatory effects                                                                                                      Protein            PTS[^†^](#t001fn002){ref-type="table-fn"}   RIA               y
                                                                                                                                                                                  PGF2α                          Multiple pro-inflammatory and immunomodulatory effects                                                                                                      Protein            PTS[^†^](#t001fn002){ref-type="table-fn"}   RIA               y
  Cootauco et al. 1993[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref073]\]                                      5/8                                                   α-2M                           Neutralization of proteinases                                                                                                                               Protein                                                        IHC               n/a
  Dong et al. 1999 \[[@pone.0167289.ref083]\]                                                                               9/11                                                  6-K-PGF1α                      Vasodilators; inhibits the aggregation of blood platelets; involved in inflammation                                                                         Protein            PTS                                         RIA               y
                                                                                                                                                                                  TXB2                           Involved in platelet aggregation, vasoconstriction and reproductive functions                                                                               Protein            PTS                                         RIA               y
  Khabbaz et al. 2001 \[[@pone.0167289.ref084]\]                                                                            15/5                                                  Endotoxins                     Induces strong immune response                                                                                                                              Protein activity   PTS                                         LAL               y
  Nakanishi et al. 2001[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref085]\]                                     10/5                                                  COX-2                          Prostaglandin synthesis                                                                                                                                     Protein                                                        IHC               n/a
  Guven et al. 2007[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref086]\]                                         12/12                                                                                                                                                                                                                                            Protein            FPT                                         IHC               n/a
  Awawdeh et al. 2002 \[[@pone.0167289.ref087]\]                                                                            46/20                                                 Substance P                    Vasoactive mediator, immune mediator                                                                                                                        Protein            PTS                                         RIA               y
  Caviedes-Bucheli et al. 2006 \[[@pone.0167289.ref088]\]                                                                   6/6                                                                                                                                                                                                                                              Protein            PTS                                         RIA               y
  Awawdeh et al. 2002 \[[@pone.0167289.ref087]\]                                                                            46/20                                                 Neurokinin A                   Generates three different preprotachykinins                                                                                                                 Protein            PTS                                         RIA               y
  Caviedes-Bucheli et al. 2006 \[[@pone.0167289.ref088]\]                                                                   6/6                                                                                                                                                                                                                                              Protein            PTS                                         RIA               y
  Awawdeh et al. 2002 \[[@pone.0167289.ref087]\]                                                                            46/20                                                 CGRP                           Vasodilation and increased microvascular permeability                                                                                                       Protein            PTS                                         RIA               y
  Caviedes-Bucheli et al. 2004 \[[@pone.0167289.ref089]\]                                                                   5/5                                                                                                                                                                                                                                              Protein            Pulp cells in suspension                    Flow cytometry    y
  Caviedes-Bucheli et al. 2005 \[[@pone.0167289.ref090]\]                                                                   6/4                                                                                                                                                                                                                                              Protein            PTS                                         RIA               y
  Caviedes-Bucheli et al. 2006 \[[@pone.0167289.ref088]\]                                                                   6/6                                                                                                                                                                                                                                              Protein            PTS                                         RIA               y
  Caviedes-Bucheli et al. 2006 \[[@pone.0167289.ref088]\]                                                                   6/6                                                   Neuro-peptide Y                Potent vasoconstrictor, parasympathetic nervous system                                                                                                      Protein            PTS                                         RIA               y
                                                                                                                                                                                  VIP                            Vasodilator, parasympathetic nervous system                                                                                                                 Protein            PTS                                         RIA               n
  da Silva et al. 2008[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref078]\]                                      6/6                                                   NOD2                           Involved in host response against bacteria                                                                                                                  mRNA               PTS                                         RT-PCR            y
  Keller et al. 2009 \[[@pone.0167289.ref056]\]                                                                             5/5                                                                                                                                                                                                                                              mRNA               PTS                                         RT-PCR            y
  **Growth Factors**                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Artese et al. 2002[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref091]\]                                        25/25                                                 VEGF                           Stimulates vasculogenesis and angiogenesis                                                                                                                  Protein            FPT                                         IHC               n/a
  Guven et al. 2007[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref086]\][\*](#t001fn001){ref-type="table-fn"}    12/12                                                                                                                                                                                                                                            Protein            FPT                                         IHC               n/a
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                                                                                                                                                                                                            Protein            PTS                                         Multiplex assay   n
  Abd-Elmeguid et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref049]\]                                  12/30                                                 FGF                            Involved in angiogenesis, wound healing, embryonic development and various endocrine signaling pathways                                                     Protein            PTS                                         Multiplex assay   n
  **Antimicrobial peptides**                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Paris et al. 2009 \[[@pone.0167289.ref050]\]                                                                              10/7                                                  hBD-1                          Activates the innate and adaptive immune system. Chemotactic for monocytes, T-lymphocytes, dendritic cells and mast cells                                   mRNA               PTS                                         RT-PCR            y
                                                                                                                                                                                  hBD-2                                                                                                                                                                                      mRNA               PTS                                         RT-PCR            n
                                                                                                                                                                                  hBD-3                                                                                                                                                                                      mRNA               PTS                                         RT-PCR            n
                                                                                                                                                                                  hBD-4                                                                                                                                                                                      mRNA               PTS                                         RT-PCR            y
  **Others**                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Caviedes-Bucheli et al. 2007 \[[@pone.0167289.ref092]\]                                                                   5/5                                                   Substance P receptor           Vasoactive mediator, immune mediator                                                                                                                        Protein            PTS                                         RIA               y
  Caviedes-Bucheli, Moreno, et al. 2008 \[[@pone.0167289.ref093]\]                                                          13/13                                                 AAMø CD163+ expressing CGRPr   Alternatively activated polarized monocyte/macrophage; different phenotype compared to the classical ones. Then expressing CD163+                           Protein            Pulp cells in suspension                    Flow cytometry    *See text*
  Suwanchai et al. 2012 \[[@pone.0167289.ref066]\]                                                                          7/18                                                  NaV 1.8                        Initiation and propagation of action potentials; involved in pain perception                                                                                Protein            PTS                                         Western blot      y
                                                                                                                                                                                  NaV 1.9                        Initiation and propagation of action potentials; involved in pain perception                                                                                Protein            PTS                                         Western blot      y
  Zhong et al. 2012 \[[@pone.0167289.ref094]\]                                                                              18/12                                                 miRNAs                         Regulators of post-transcriptional gene expression in biological processes like inflammation, immune response, and osteoclastic bone resorption             mRNA               PTS                                         Microarray        *See text*
  Dong et al. 2013[\*](#t001fn001){ref-type="table-fn"} \[[@pone.0167289.ref095]\][\*](#t001fn001){ref-type="table-fn"}     21/12                                                 EphA7                          Involved in embryonic development, angiogenesis, tumorigenesis, inflammation & pain                                                                         Protein            FPT                                         IHC               y
                                                                                                                                                                                                                                                                                                                                                                             mRNA               PTS                                         RT-PCR            y

\* Pulpal inflammation confirmed histologically;

^†^ Substrate pooled before analysis;

y: Yes; n: No; n/a: Not applicable.

Analytes were mostly either pulp tissue supernatant (PTS) or fixed pulp tissue (FPT). One study used pulp cells in suspension, another one pulpal fluid. Analytical methods used included reverse transcription polymerase chain reaction (RT-PCR), multiplex assay, microarray, Western Blot, radioimmunoassay (RIA), immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), zymography, flow cytometry, limulus amoebocyte assay (LAL), and specific enzyme assays.

10.1371/journal.pone.0167289.t002

###### Studies assessing other substrates than pulp tissue for the presence of a biomarker.

![](pone.0167289.t002){#pone.0167289.t002g}

  Reference                                          *n* in group (irreversibly inflamed/ non-inflamed)   Biomarker    Function                                                                                                   Target             Analyte                      Analysis       Significant difference between groups
  -------------------------------------------------- ---------------------------------------------------- ------------ ---------------------------------------------------------------------------------------------------------- ------------------ ---------------------------- -------------- ---------------------------------------
  **Cytokines**                                                                                                                                                                                                                                                                                  
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 IL-1α        Regulates immune and inflammatory reactions; stimulates bone resorption                                    Protein            PB                           ELISA          n
                                                                                                          IL-1β        Regulates immune and inflammatory reactions; stimulates bone resorption                                    Protein            PB                           ELISA          n
  Elsalhy et al. 2013 \[[@pone.0167289.ref045]\]     43/25                                                IL-2         Regulates the activities of leukocytes                                                                     Protein            PB                           ELISA          n
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 IL-6         Regulator of T- and B-cell growth, acute phase protein production                                          Protein            PB                           ELISA          *Not detected*
  Elsalhy et al. 2013 \[[@pone.0167289.ref045]\]     43/25                                                                                                                                                                        Protein            PB                           ELISA          y
  Karapanou et al. 2008 \[[@pone.0167289.ref001]\]   17/17                                                IL-8         Recruitment and activation of neutrophils                                                                  Protein            GCF                          ELISA          y
  Elsalhy et al. 2013 \[[@pone.0167289.ref045]\]     43/25                                                                                                                                                                        Protein            PB                           ELISA          y
  Elsalhy et al. 2013 \[[@pone.0167289.ref045]\]     43/25                                                IL-10        Multiple effects in immunoregulation and inflammation; anti-inflammatory                                   Protein            PB                           ELISA          y
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 TNF-α        Delays neutrophil apoptosis                                                                                Protein            PB                           ELISA          n
  Karapanou et al. 2008 \[[@pone.0167289.ref001]\]   25/25                                                                                                                                                                        Protein            GCF                          ELISA          *Not detected*
  Elsalhy et al. 2013 \[[@pone.0167289.ref045]\]     43/25                                                                                                                                                                        Protein            PB                           ELISA          y
  Elsalhy et al. 2013 \[[@pone.0167289.ref045]\]     43/25                                                IFN-γ        Cytokine that is critical for innate and adaptive immunity                                                 Protein            PB                           ELISA          y
  **Proteases and other enzymes**                                                                                                                                                                                                                                                                
  Zehnder et al. 2011 \[[@pone.0167289.ref033]\]     16/12                                                MMP-9        Hydrolysis of intercellular matrix; regulatory factor for neutrophil migration across basement membranes   Protein activity   Dentinal fluid               Enzyme assay   y
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 Elastase     Cleavage of elastin, collagen, proteoglycans                                                               Protein            PB                           ELISA          y
  **Vasoactive agents**                                                                                                                                                                                                                                                                          
  Lepinski et al. 2000 \[[@pone.0167289.ref041]\]    11/10                                                Bradykinin   Vasodilator involved in pain and inflammation mechanisms                                                   Protein            Extracellular pulpal fluid   RIA            y
  Bowles et al. 2003 \[[@pone.0167289.ref042]\]      16/8                                                                                                                                                                         Protein            Extracellular pulpal fluid   RIA            y
  **Others**                                                                                                                                                                                                                                                                                     
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 IgG          Antigen neutralization                                                                                     Protein            PB                           ELISA          y
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 IgA          Antigen neutralization                                                                                     Protein            PB                           ELISA          y
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 IgM          Antigen neutralization                                                                                     Protein            PB                           ELISA          y
  Nakanishi et al. 1995 \[[@pone.0167289.ref044]\]   27/9                                                 PGE2         Multiple pro-inflammatory and immunomodulatory effects                                                     Protein            PB                           ELISA          y
  Evcil et al. 2006 \[[@pone.0167289.ref046]\]       16/16                                                Serum NO     Cellular signaling molecule involved in many physiological and pathological processes                      Protein activity   Peripheral blood serum       Serum assay    n

y: Yes; n: No.

Analytes were mostly either pulpal blood (PB) or gingival crevicular fluid (GCF). Extracellular pulpal fluid and peripheral serum were used in one study each. Analytical methods used included radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and specific serum or enzyme assays.

![Bar chart showing the quality ratings of the included studies based on a modified Newcastle-Ottawa-Scale.](pone.0167289.g003){#pone.0167289.g003}

Tissues Studied {#sec012}
---------------

Eighty-eight percent of the studies included (50/57; [Table 1](#pone.0167289.t001){ref-type="table"}) analyzed pulp tissue for the presence of a biomarker either collected via pulpectomy (N = 5), tooth extraction and fracturing (N = 25), or a combination of both (N = 20). Twelve percent (7/57; [Table 2](#pone.0167289.t002){ref-type="table"}) of the studies included analyzed substrates other than pulp tissue: pulpal blood (N = 2), peripheral blood serum (N = 1), GCF (N = 1), dentinal fluid (N = 1), or extracellular pulpal fluid (N = 2). Pulpal blood, GCF and dentinal fluid were collected using absorbable membranes, blood serum via peripheral blood collection and extracellular pulpal fluid by inserting microdialysis membranes into vital pulp tissue \[[@pone.0167289.ref041], [@pone.0167289.ref042]\]. Eighty-two percent of the studies analyzing pulp tissue (41/50) used tissue collected from extracted healthy, non-carious permanent, or wisdom teeth as their control. Fourteen percent (7/50) used healthy pulp tissue collected via pulpectomy because of elected root canal treatment for prosthetic reasons as their control. One study used tissues from extraction and pulpectomy as control \[[@pone.0167289.ref043]\], another one did not state precisely how they collected control tissue \[[@pone.0167289.ref002]\]. Of the 7 studies evaluating substrates other than pulp tissue, two sampled blood \[[@pone.0167289.ref044], [@pone.0167289.ref045]\], and another one extracellular fluid \[[@pone.0167289.ref041]\] from healthy teeth that were assessed but subsequently planed for extraction because of prosthetic or orthodontic reasons as control. One study sampled venous (peripheral) blood during pulp inflammation and used a consecutive peripheral blood sample after treatment as control \[[@pone.0167289.ref046]\]. One further study sampled GCF from healthy contralateral or adjacent teeth as control \[[@pone.0167289.ref001]\], and another one collected dentinal fluid from non-symptomatic teeth scheduled for replacement of a filling as control \[[@pone.0167289.ref033]\]. The substrate in one study was pooled before performing the confirmatory test \[[@pone.0167289.ref047]\].

Confirmatory Tests {#sec013}
------------------

Analytical methods used for the assessment of pulp tissue included reverse transcription polymerase chain reaction, multiplex assay, microarray, western blot, radioimmunoassay, immunohistochemistry, enzyme-linked immunosorbent assay, zymography, flow cytometry, limulus amoebocyte assay and specific enzyme assays ([Table 1](#pone.0167289.t001){ref-type="table"}). Pulpal inflammation was confirmed by histology in 42% (21/50; [Table 1](#pone.0167289.t001){ref-type="table"} and [S5 Table](#pone.0167289.s005){ref-type="supplementary-material"}) of these studies. Substrates other than pulp tissue were analyzed using radioimmunoassay, enzyme-linked immunosorbent assay, specific serum, or enzyme assays ([Table 2](#pone.0167289.t002){ref-type="table"}). Histology was not used to confirm pulpal diagnosis in those studies. Seventy-four percent of the studies evaluating pulp tissue (37/50) analyzed actual protein expression or protein activity, whereas 16% (8/50) analyzed the pulp tissue on the DNA level. Five studies (10%) analyzed the pulp tissue substrates at both levels ([Table 1](#pone.0167289.t001){ref-type="table"}). All studies evaluating other substrates than pulp tissue evaluated protein expression or protein activity ([Table 2](#pone.0167289.t002){ref-type="table"}).

Markers Studied {#sec014}
---------------

Pulp tissue was assessed for a total of 89 biological markers. Statistical significant differences between an irreversible inflamed and a healthy pulp could be detected for 64 biological markers (71.9%) by at least one study. Nineteen biological markers showed no statistically significant differences between inflammation and health, whereas 6 biological markers were not evaluated employing statistical tests ([Table 1](#pone.0167289.t001){ref-type="table"}). Substrate other than pulp tissue was evaluated for 16 biological markers. For twelve biological marker (75%) statistical significant differences between irreversible inflammation and health could be detect by at least one study.

Discussion {#sec015}
==========

The results point to a response in pulpitis by immunocompetent tissues that ultimately results in the release of mediators, which in turn trigger a series of inflammatory events and an attempt to initiate repair. Collectively, the data presented here demonstrate the involvement of various TLR-induced chemotactic molecules (i.e. IL-8, CXCL-10, MIP family, GRO, MCP family, RANTES, Eotaxin, IP10, and others).

TLRs have been shown to confer immunocompetence to the dental pulp \[[@pone.0167289.ref056]\]. They are expressed by both immune and non-immune cells in the pulp including neurons, fibroblasts, endothelial cells, epithelial cells and others, which recognize viral and microbial structures as well as self molecules (such as single stranded RNAs) that may accumulate in non-physiologic amounts or sites during inflammation \[[@pone.0167289.ref096]--[@pone.0167289.ref100]\].

Under normal conditions, very few immune cells are present in the dental pulp \[[@pone.0167289.ref101]\]. In the presence of infection (i.e. caries), immune cells are recruited to the pulp even in the absence of direct bacterial contact on the pulp tissue itself. The permeability of dentin to soluble bacterial products allows pulpal response to occur prior to carious pulpal exposure. These soluble bacterial products, along with components of the complement system and products of the lipoxygenase pathway of arachidonic acid metabolism are chemotactic for leukocytes \[[@pone.0167289.ref102]\].

The exponential increase in the number of infiltrating leukocytes brings with it a corresponding increase in lysosomal enzymes that cause tissue damage. Proteases like elastase and MMPs (Tables [1](#pone.0167289.t001){ref-type="table"} and [2](#pone.0167289.t002){ref-type="table"}) cleave elastin and proteoglycans that destroy the pulp tissue resulting in irreversible damage \[[@pone.0167289.ref033], [@pone.0167289.ref058], [@pone.0167289.ref063]\]. Furthermore, the accompanying spike in inflammatory mediators like PGE2, cAMP, COX-2, CGRP, neurokinins and others stimulate vasodilation and microvascular permeability by binding into their respective receptors (i.e. EP2/3 receptor for PGE2) and induce cytoskeletal rearrangement or contraction of vascular smooth muscle \[[@pone.0167289.ref103]\].

Equally as important is the action of neuropeptides (e.g. substance P, calcitonin-gene related peptide) ([Table 1](#pone.0167289.t001){ref-type="table"}). These neuropeptides typically reside in endings of afferent nerve close to blood vessels but also associated with macrophages and odontoblasts \[[@pone.0167289.ref104]\]. As a response to stimuli, afferent nerve sprouting has been demonstrated, and with it an increase in neuropeptide concentration \[[@pone.0167289.ref105]\], which can cause spontaneous pain, allodynia or hyperalgesia in teeth with pulpitis.

Simultaneous to the destructive effects of leukocytic infiltration is the capability of these cells to induce repair through the release of VEGF, TGF-B, GM-CSF and others (Tables [1](#pone.0167289.t001){ref-type="table"} and [2](#pone.0167289.t002){ref-type="table"}) that induce alterations of the local extracellular matrix, promote induction of endothelial cells to migrate or proliferate, and inhibition of vascular growth with formation of differentiated capillaries \[[@pone.0167289.ref106]\]. The increased expression in inflamed pulp of toll-mediated human beta-defensins (hBD) \[[@pone.0167289.ref050]\] that play an important role in the innate host defense against bacterial invasion, contribute to promotion of adaptive immune responses, and show chemotactic activities further underscore the dynamic range of response of the dental pulp during inflammation. In addition, it can also be appreciated that during pulpal inflammation, the anti-inflammatory effects of various mediators such as tissue inhibitors of matrix proteinases (TIMPs), siRNA \[[@pone.0167289.ref094], [@pone.0167289.ref107]\] and others also come into play.

As a direct result of the release of inflammatory biomarkers, pulpal responses include classical signs of inflammation specifically a vascular response, along with changes in mediator profiles and cellular constituents. The transition from reversible to irreversible pulpitis has been broadly characterized by a migration of dendritic cells towards odontoblasts and accumulation of immune cells \[[@pone.0167289.ref108]\]. However, a more detailed analysis such in the majority of studies included in this paper evaluating biomarkers of pulpal inflammation demonstrates (statistical) significant differences between a clinically diagnosed healthy or irreversibly inflamed pulp at the molecular level.

Moreover, the analytes were obtained via different approaches both from the pulp directly as well as indirectly from tissue fluid. [Fig 4](#pone.0167289.g004){ref-type="fig"} illustrates the potential sampling sites for molecular pulpal diagnostics \[[@pone.0167289.ref034]\]. While having the benefit to show a direct picture of intrapulpal conditions using pulpal blood \[[@pone.0167289.ref026]\] or whole pulp tissue requires access to the pulp space and is therefore not applicable as a chairside screening tool. Conversely, indirect methods such as dentin fluid collection or assessment of mediators in GCF can be performed clinical in a less invasive way. Dentin fluid is the extracellular fluid that is contained within dentinal tubules \[[@pone.0167289.ref109]\]; its composition includes inflammatory mediators and vasoactive compounds associated with inflammation. While initial evidence suggested that these mediators can be assayed \[[@pone.0167289.ref033]\] problems exist with protein yield \[[@pone.0167289.ref027]\] and the need to remove the existing restoration or in other cases to prepare an initial cavity deep in dentin.

![Actual and potential sampling sites to assay pulpal mediators.](pone.0167289.g004){#pone.0167289.g004}

GCF was used to sample mediators in one study included here ([Table 2](#pone.0167289.t002){ref-type="table"}) \[[@pone.0167289.ref001]\]. This fluid is an exudate that from the gingival crevice and it contains several host factors including antibodies, bacterial antigens, proteins, and cytokines \[[@pone.0167289.ref110], [@pone.0167289.ref111]\]. GCF analyses may be promising due to the ease of application. Moreover, it may be possible to assess the dynamics of apical periodontitis using GCF \[[@pone.0167289.ref034]\]. However, the major drawback in the evaluation of host mediators in GCF is that tissue inflammation, independent of its cause, is a non-specific process of innate immunity \[[@pone.0167289.ref112]\] and this makes it difficult to distinguish on a molecular level between a marginal and apical periodontal inflammation. When sampling from the GCF for pulpal diagnostics, this potential drawback could be overcome by (i) creating healthy periodontal conditions, (ii) averaging out several sites on one or multiple teeth, (iii) combining clinical and radiographic observations, or (iv) defining a specific pattern of metabolites relevant to the pulp and not the periodontium, or possibly by other as yet unidentified means. Furthermore, the detection of mediators of pulpitis in GCF is impacted by the need for these compounds to reach the periodontal ligament and ultimately the gingival crevice in sufficient concentrations. Indeed, the notion that mediators will diffuse from the pulp via dentinal tubules or accessory canals to the periodontal ligament has been called into question \[[@pone.0167289.ref087]\]. Periapical fluid samples, while requiring a direct access to the apical site, are of interest to determine the level of systemic inflammation \[[@pone.0167289.ref028]\].

Discovering an improved method to determine the present inflammatory condition of the pulp could be of great value: on the one hand, pulp necrosis is one of the most frequent complications after coronal restoration of assumed non-inflamed (vital) teeth, on the other performing a full pulpectomy on teeth that could have been kept vital (at least in part) suggests that overtreatment may occur in many cases \[[@pone.0167289.ref113]\]. Endodontic diagnosis should therefore focus on either the extent of the microbial infection or the inflammatory reaction of the host tissue; however, current methods do neither \[[@pone.0167289.ref014], [@pone.0167289.ref023], [@pone.0167289.ref034]\].

Keeping a pulp vital offers distinct advantages compared to root canal treatment: the protective immune capacity of the pulp remains preserved and the remaining tooth structure gets not unnecessarily weakened by access cavity preparation and root canal enlargement. Unfortunately, the only available long-term outcome studies on direct pulp capping procedures (i.e. direct pulpal interventions), which attempt to maintain pulpal vitality, show unsatisfactory success rates as low as 20% after ten years \[[@pone.0167289.ref114]\]. The development of biocompatible materials facilitates a wound closure free of inflammation after pulpal capping procedures or partial pulpotomy \[[@pone.0167289.ref108]\]. However, the likelihood of a pulp to survive such procedures remains questionable using current schemes for assessment of pulpal inflammation.

One limitation of this systematic review is that merely 2 out of 57 studies \[[@pone.0167289.ref033], [@pone.0167289.ref045]\] were specifically designed to investigate potential biomarkers in the context of pulpal diagnostics. Most of the studies analyzed here merely target the presence of molecules and their function in pulpal inflammation. Nevertheless, based on the current state of knowledge this review provides an overview on molecules that are present and measurable during pulpal inflammation and therefore potentially can serve as a biomarker for pulpal inflammation. This may provide impulses for further research. This research needs to explore patient (age, gender, systemic condition) and infection related factors (varying composition of the microbiological infection). Clinical investigations should be conducted that are specifically designed to confirm the results collected from the research collected here. More specifically mediator profiles should be assessed in defined clinical scenarios. In addition, the assays methodology should be tested for their applicability with the possible substrates. The ultimate goal should then be to develop an inexpensive chairside test for non-invasive molecular pulp diagnostics. In fact, such a chair-side assay, based on the immunochromatographic detection of MMP-8 specific antibodies, is already commercial available to diagnose periodontal inflammation \[[@pone.0167289.ref115]\]. For endodontic procedures of the future, such as partial pulpotomies and pulp regeneration, a comparable test will be of significant value.

Indeed, various biomarkers that are produced by cellular components of the dental pulp can provide a snapshot of the biological mechanisms that propel this immunocompetent tissue towards healing or necrosis. The imbalance between tissue destructive molecules like proteases and tissue inductive molecules like VEGF may serve as a diagnostic or prognostic tool for endodontic intervention. The challenge remains on developing a method to make these biomarkers readily measureable in a clinical setting.

Conclusions {#sec016}
===========

In the included studies, irreversible pulpitis was associated with different expression of various biomarkers compared to non-inflamed controls. These biomarkers were significantly expressed not only in pulp tissue, but also in gingival crevicular fluid that can be collected non-invasively and in dentin fluid that can be analyzed without extirpating the pulpal tissue. This may be used to accurately differentiate diseased from healthy pulp tissue. The main current challenges in the clinical application of biomarkers lie in the identification of biomarkers or biomarker subsets that reliably correlate with pulpal inflammation, the improvement of sample collection (substrate and protein yields), and their analysis (interference of the biomarkers with inflammation of other than pulpal origin). If these hurdles can be overcome, a more accurate pulpal diagnosis and more predictable vital pulp treatment regime may create better clinical outcomes.
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